IDH1 and central nervous system cancer: Although many studies and reviews have shown that CDKN2A/B deletion is associated with poor prognosis in diffuse glioma with IDH1/2 mutation [3,11,12,18], relatively few have reported comprehensively on CNS WHO grade 4 gliomas.